US Press Releases and News
Navigate within 'US Press Releases and News'
Novartis Group calls on FDA to maintain the well-established naming policy for all biologics to help ensure patient safety
Basel, Switzerland, October 30, 2013
Novartis announced today it has filed a Citizen Petition with the US Food and Drug Administration (FDA), urging the Agency to require that a biosimilar share the same INN as the reference product.
Sandoz Applauds Governor Brown For Vetoing California Biosimilars Bill
California, USA, October 15, 2013
Sandoz welcomes California Governor Jerry Brown’s veto of legislation that threatened to restrict patient access to biosimilars – high-quality follow-on versions of existing biologic medicines to treat complex disorders including cancer and autoimmune diseases.
Sandoz launches an authorized generic of key oncology product VIDAZA®
Princeton, New Jersey, September 23, 2013
Sandoz today announced the US launch of azacitidine for injection, an authorized generic version of Celgene’s VIDAZA®.
Sandoz launches an authorized generic version of temozolomide capsules
Princeton, New Jersey, August 13, 2013
Sandoz today announced the US launch of temozolomide capsules.
US Federal Circuit Court of Appeals finds Sandoz’s generic Copaxone® does not infringe Teva’s 2015 patent
Princeton, New Jersey, July 26, 2013
Sandoz announced today that the US Federal Circuit Court of Appeals has invalidated several patents asserted against the company by Teva Pharmaceuticals in litigation concerning a generic version of Copaxone® – one of the leading products marketed for the treatment of multiple sclerosis.